|Bid||7.36 x 1100|
|Ask||7.41 x 800|
|Day's Range||7.25 - 7.48|
|52 Week Range||3.81 - 21.68|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.71|
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced the appointment of David Nassif as Chief Financial Officer, effective July 1, 2019. In addition, Axovant announced the expansion of its Board of Directors with the addition of Mr. Senthil Sundaram.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, announced two posters at the 5th Congress of the European Academy of Neurology (EAN) to be presented by Paul Korner, MD, SVP, Clinical Development and Medical Affairs.
Axovant Gene Therapies (NASDAQ:AXGT) saw its stock skyrocket on Friday as the company inked a deal with Yposkesi related to the manufacturing of the biopharmaceutical business' experimental treatments.Axovant is partnering up with the French contract development and manufacturing business in order to reserve manufacturing capacity for the company's experimental treatments, granting Axovant preferred access and reserved capacity for viral vector production. The move also gives the company expertise in process development, technology transfer and quality control, per a statement from the biopharma business."This partnership is expected to provide Axovant with sufficient manufacturing capacity to deliver our gene therapies to patients at scale, a key component for the continued development of our gene therapy pipeline," Axovant CEO Pavan Cheruvu said in the company's statement.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAxovant has no manufacturing capacity of its own, which means the business depends on partnerships as it works to bring its first therapies to market. The company currently has agreements with Oxford BioMedica, as well as Nationwide Children's Hospital to supply material.Yposkesi is focused on gene therapy work, and the company has plans in place to double its manufacturing capacity for AAV and lentiviral vectors to 100,000 square feet, per the companies' statement. The brand also plans on creating additional large-scale bioreactors.CEO Alain Lamprove said Yposkesi will seek to help Axovant accelerate the development of its treatments, which includes therapies in clinical testing for Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis.AXGT stock is up a whopping 30.9% on Friday following the news. More From InvestorPlace * 7 Value Stocks to Buy for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 Compare Brokers The post Axovant Gene Therapies News: AXGT Stock Soars on Manufacturing Deal appeared first on InvestorPlace.
Axovant Gene Therapies Ltd (NASDAQ: AXGT ) shares were trading higher off the open Thursday after it announced a tie-up with a contract development and manufacturing organization, or CDMO. What Happened ...
BASEL, Switzerland and CORBEIL-ESSONNES, France, June 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announces it has signed a strategic partnership with Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production. Under this strategic collaboration, Yposkesi will provide expertise in process development, technology transfer, manufacturing scale-up, quality control and quality assurance.
Axovant Gene Therapies Ltd NASDAQ/NGS:AXGTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AXGT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding AXGT is favorable, with net inflows of $1.20 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Axovant (AXGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
Established diversified pipeline of three clinical-stage gene therapy programs for serious neurological disorders including Parkinson’s disease, GM1 gangliosidosis, and.
Axovant Gene Therapies, Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today reported six-month follow-up data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease. AXO-Lenti-PD was observed to be generally well tolerated, with no serious adverse events related to the product or the procedure and patients showed continued improvement from baseline across multiple measurements. “Our patient-focused goal of improving motor function, reducing dyskinesia, lowering the requirement for oral levodopa, and improving quality of life is made possible by the continuous dopamine replacement strategy of AXO-Lenti-PD gene therapy.
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.
BASEL, Switzerland, May 31, 2019 -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan.
Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.
Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.